Intellia Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker NTLA, with headquarters in Cambridge, Massachusetts, United States. Founded in 2014, Intellia has become one of the most closely watched companies in the next-generation gene-editing space, particularly for in vivo CRISPR-based therapies. For international investors, it fits the classic clinical-stage biotech profile: heavy R&D investment, no meaningful commercial revenues yet, and valuation driven primarily by clinical execution, regulatory milestones, and the long-term promise of its platform. ([ir.intelliatx.com](https://ir.intelliatx.com/?utm_source=openai)) Intellia’s core business is the development of one-time treatments designed to edit DNA directly inside the body. The company targets severe diseases with high unmet medical need, especially liver-related conditions, rare genetic disorders, and selected indications where a durable intervention could replace chronic therapy. Intellia emphasizes its CRISPR capabilities and related enabling technologies to build potentially long-lasting treatments with a fundamentally different economic model than recurring-dosing drugs. Its portfolio is currently centered on two flagship programs: nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin amyloidosis, and lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema. ([ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-8?utm_source=openai)) From a competitive standpoint, Intellia holds a leading position among CRISPR-focused biotechs, alongside other gene-editing specialists. Its relative strengths include a strong scientific franchise, a clear focus on in vivo editing, and the ability to advance programs into late-stage clinical development. At the same time, the investment case remains inherently high risk: value creation depends on trial outcomes, regulatory approvals, and the company’s ability to scale an industrial and commercial model that is still largely pre-revenue. ([ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-8?utm_source=openai)) Recent developments are especially important. In March 2026, the FDA lifted the clinical hold on MAGNITUDE, the Phase 3 trial of nex-z in ATTR-CM. In April 2026, Intellia reported positive Phase 3 topline data for lonvo-z in hereditary angioedema, initiated a rolling BLA submission to the FDA, and also announced a public equity offering. These events mark a pivotal period for the company, with major regulatory and capital-markets catalysts in the near term. ([ir.intelliatx.com](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-lift-clinical-hold-0?utm_source=openai)) In short, Intellia Therapeutics is a high-risk, high-upside growth biotech with differentiated CRISPR technology, a late-stage pipeline, and meaningful near-term catalysts on the NASDAQ market in the United States.